Advertisement
Advertisement
U.S. markets open in 4 hours 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

IRRAS AB (publ) (IRRAS.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
3.3800-0.0650 (-1.89%)
As of 10:26AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4450
Open3.3500
Bid3.3500 x 0
Ask3.3800 x 0
Day's Range3.3500 - 3.4100
52 Week Range2.9950 - 7.9300
Volume769
Avg. Volume86,321
Market Cap268.647M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-1.8660
Earnings DateFeb 14, 2022 - Feb 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IRRAS.ST

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      IRRAS Announces publication of a Case report from Buffalo General Medical Center, highlights clinical superiority of IRRAflow treatment versus traditional drainage

      IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the publication of a clinical case report entitled, "Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Using IRRAflow Self-Irrigating Catheter" in the Cureus Journal of Medical Science.1

    • PR Newswire

      IRRAS Announces Notified Body Transition from GMED to DEKRA, a Global Leader in Inspection and Certifications

      IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced today that the CE Mark certificates for its IRRAflow system and the company's ISO13485:2016 certification have been transferred to a new notified body, DEKRA. After the successful completion of a recent audit by DEKRA, these CE Mark certificates for IRRAflow will remain valid until May 2024.

    • PR Newswire

      IRRAS AB publishes Interim Report for the period January to March 2021

      "During Q1, the global installed base for IRRAS products increased; the total number of IRRAflow systems increased from 73 to 84 and Hummingbird systems grew from 5 to 9. An increase in the number of systems shipped is important, but it is more critical to convert evaluations into revenue-generating commercial customers. During the quarter, two influential US comprehensive stroke centers, Buffalo General Medical Center and West Virginia University, placed commercial disposable stocking orders for IRRAflow. The contracts signed by these customers more than doubled the number of commercial IRRAflow control units (from 9 to 19) and will generate recurring revenue as usage continues.

    Advertisement
    Advertisement